$599
Basal Insulin, Bolus Insulin, Dual/triple agonist, GLP-1RA, Insulin Delivery, Other, SGLT2i

Lilly Launches Mounjaro in the UK; Mannkind Completes INHALE-1 Enrollment; Diamyd Receives Fast Track Designation in T1DM; Alnylam Q4 ’23 Earnings

A series of cardiometabolic-related news items have been observed from Lilly, Mannkind, Diamyd, and Alnylam. Below, FENIX provides highlights and insights for the respective news items.

This content is for Read Less members only.
Register
Already a member? Log in here
OR
Return to Home